Surrozen Inc Ordinary Shares SRZN 深 沪
已收盘 09-05 16:00:00 美东时间
12.20
-0.250
-2.01%
华盛通- 最 高13.25
- 今 开13.25
- 成交量 1.06万股
- 最 低 11.75
- 昨 收 12.45
- 总市值 1.04亿
- 52周最高 18.17
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 5.90
- 委 比 -89.52%
- 总股本 856.26万
- 历史最高 210.00
- 量 比 0.56
- 振 幅 12.05%
- 历史最低 4.50
- 每 手 1
- 风险率 2.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Surrozen, a biotech company focusing on治疗严重眼病的靶向疗法，于9月2日向四位新员工授予总计45,710股的股票期权。这些期权的行权价为每股12.32美元，归属期为4年，分月归属。此举措符合纳斯达克上市规则，并需员工持续服务至各归属日期。选项已由公司薪酬委员会批准，作为吸引新员工加入的激励措施。
09-04 20:15
Surrozen Signs $50M Sales Agreement with TD Securities
The latest update is out from Surrozen ( ($SRZN) ). On August 29, 2025, Surroze...
08-30 05:15
Surrozen GAAP EPS of $2.55
Surrozen press release (NASDAQ:SRZN): Q2 GAAP EPS of $2.55. Net: Other income, net was $16.2 million, compared to $3.7 million for the same period in 2024. The variance is primarily attributable to a ...
08-12 03:12
Surrozen’s Q2 2025: Progress in Eye Disease Therapies
Surrozen, Inc. ( ($SRZN) ) has released its Q2 earnings. Here is a breakdown of...
08-09 12:18
Surrozen Q2 EPS $2.55 Beats $(1.11) Estimate, Sales $983.000K
Surrozen (NASDAQ:SRZN) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $(1.11) by 329.73 percent. This is a 131.91 percent increase over losses of $(7.99) per share from the
08-09 04:09
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Surrozen, a biotech company focused on Wnt pathway therapeutics for severe eye diseases, reported Q2 2025 results. Key highlights include专利授予，领导层任命，临床咨询委员会成立，科学展示以及财务表现。Daniel Chao博士加入担任临床开发负责人。Surrozen ophthalmology pipeline continues with SZN-8141 and SZN-8143 candidates, targeting retinal diseases. Financially, the company had $90.4 million in cash, increased R&D expenses, and net income of $39.7 million. Dr. Craig Parker emphasized momentum i...
08-08 20:05
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen, Inc. will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. The presentation will begin at 7:00 AM Eastern Time and can be accessed via the Investors section of Surrozen's website. The company specializes in developing tissue-specific antibodies targeting the Wnt pathway for severe eye diseases.
08-06 20:30
Surrozen Granted US Patent To Antibody-Based Molecules Targeting Key Receptors In Wnt Pathway
Newly granted patent is part of the expanding intellectual property portfolio directed to:-generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and-incorporating novel
05-14 20:38
美股大行评级 | 潜在涨幅455.56%！Medicus Pharma获D. Boral Capital升目标价至27美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital：维持Medicus Pharma(MDCX)"买入"评级，目标价从14美元升至27美元</p> <p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从
05-13 08:50
